Expertise in

conditions

Hirokazu Nagai

Nagoya, JP

Expertise in

conditions

Nagoya, JP

Overview

Hirokazu Nagai practices practicing medicine in Nagoya, Japan.

Nagai is highly rated in 15 conditions, according to our data. Their clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Peripheral T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 185 peer reviewed articles and participating in 5 clinical trials.

Locations

Nagoya, Japan

Other Locations

Chiyoda, 1000006, Japan

Tokyo, Japan

Sendai, Japan

Wakayama, Japan

Kobe, Japan

Tohoku, Japan

Tsukuba, Japan

Hongo, 1138656, Japan

Setagaya, 1568550, Japan

Kyoto, Japan

Tokushima, Japan

Fukuoka, Japan

Naka, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

Enrollment Status: Active_not_recruiting

Publish Date: May 15, 2026

Intervention Type: Drug

Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib

Study Phase: Phase 3

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

Enrollment Status: Active_not_recruiting

Publish Date: April 24, 2026

Intervention Type: Drug

Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab

Study Phase: Phase 3

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

Enrollment Status: Active_not_recruiting

Publish Date: January 29, 2026

Intervention Type: Drug

Study Drugs: Pirtobrutinib, Venetoclax, Rituximab

Study Phase: Phase 3

A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: January 22, 2026

Intervention Type: Drug

Study Drugs: Pirtobrutinib, Bendamustine, Rituximab

Study Phase: Phase 3

Phase 1/2 Study of TAK-981 in Combination With Rituximab in Patients With Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma

Enrollment Status: Terminated

Publish Date: June 14, 2024

Intervention Type: Drug

Study Drugs: TAK-981, Rituximab

Study Phase: Phase 1/Phase 2

View 4 Less Clinical Trials

185 Total Publications

Hybrid Supercharged Antibodies: A Rational Approach to Boost Immunoassay Sensitivity via Controlled Nanoparticle Adsorption.

Journal: Langmuir : the ACS journal of surfaces and colloids

Published: April 03, 2026

View All 185 Publications

Frequently Asked Questions about Hirokazu Nagai

Is Hirokazu Nagai a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Hirokazu Nagai is classified as an Elite expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hirokazu Nagai participate in research or clinical trials?

Yes. Hirokazu Nagai has published 185 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Hirokazu Nagai's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Nagai's expertise for a condition

ConditionClose